The primary objective of the Pathology, Imaging and Flow Cytometry Core is to provide accurate phenotypic characterization of pulmonary vascular remodeling and inflammation in relevant models of PH. To accomplish these goals, we integrate high quality tissue processing, immunohistochemistry, and stereology with flow cytometry (FACS) to inform on the participation of inflammatory and structural cells in pulmonary hypertension in all three projects. To accomplish these goals, the following specific Aims are proposed:
Specific Aim 1 : To provide qualitative and quantitative assessment of pulmonary vascular remodeling in lungs of cows, rats, and mice in Projects 1-3. We propose 4 specific tasks to support this specific aim, which include: planning of experiments (task 1), collection, processing, and phenotyping experimental lungs (task 2), morphology and stereology of pulmonary vascular remodeling (task 4), and integration of morphological data with specific project goals and aims (task 9).
Specific Aim 2 : To determine expression patterns and abundance of candidate molecules investigated in experimental lungs. We propose 5 specific tasks to support this specific aim, which include planning of experiments (task 1), tissue processing (task 2), morphology and stereology (task 3), laser capture microdissection (LCM; task 7), flow activated cell sorting (FACS) (task 8), and integration of morphological data with specific project goals and aims (task 9).
Specific Aim 3 : To obtain high quality mRNA and DNA from specific pulmonary vascular structures and lesions from animals manipulated in Projects 1-3. We propose 5 specific tasks to support this specific aim, which include planning of experiments (task 1), tissue processing (task 2), LCM (task 7), and FACS (task 8), and integration of morphological data with specific project goals and aims (task 9).
Specific Aim 4 : To translate the key expression findings in Specific Aim 2 to human control and PAH lungs. We propose six specific tasks to support the specific aim, which include planning of experiments (task 1), tissue processing (task 2), human tissue studies (with Core B) (task 3), morphology and stereology (task 4), LCM (task 7), and integration of morphological data with specific project goals and aims (task 9). Foremost in accomplishing these goals is the scientific expertise within the leadership of the core. Core C is led by of Drs. Rubin M. Tuder, an experimental and practicing pulmonary pathologist with major expertise in pathology and pathobiology of pulmonary hypertension, William Jansen and Phil Simonian, who have extensive expertise in lung inflammation and macrophage biology. The novelty of the Core C lies on the unique resources, unmatched expertise, and overall experimental breadth, allowing for the integration and human translation pertaining to all three projects. PHS 398/2590 (Rev. 09/04) Page Continuation Format Page

Public Health Relevance

The primary objective of the Pathology, Imaging and Flow Cytometry Core is to provide accurate assessment of the extent and the type of changes in pulmonary arteries in animals used in the experiments used in each of the projects. We will also use flow cytometry to quantify and characterize the inflammatory cells in each project and will perform studies using normal and diseased lung tissue with pulmonary hypertension. We are fully equipped and have the technical expertise to carry out these tasks. PHS 398/2590 (Rev. 09/04) Page Continuation Format Page

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL014985-43
Application #
9307906
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Xiao, Lei
Project Start
Project End
Budget Start
2017-07-01
Budget End
2018-06-30
Support Year
43
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Blum, Lisa K; Cao, Richard R L; Sweatt, Andrew J et al. (2018) Circulating plasmablasts are elevated and produce pathogenic anti-endothelial cell autoantibodies in idiopathic pulmonary arterial hypertension. Eur J Immunol 48:874-884
Kumar, Rahul; Graham, Brian (2018) IL-33-HIF1? Axis in Hypoxic Pulmonary Hypertension. EBioMedicine 33:8-9
Ding, Yonghui; Xu, Xin; Sharma, Sadhana et al. (2018) Biomimetic soft fibrous hydrogels for contractile and pharmacologically responsive smooth muscle. Acta Biomater 74:121-130
Kumar, Rahul; Graham, Brian (2018) How does inflammation contribute to pulmonary hypertension? Eur Respir J 51:
Jiang, Xinguo; Nicolls, Mark R; Tian, Wen et al. (2018) Lymphatic Dysfunction, Leukotrienes, and Lymphedema. Annu Rev Physiol 80:49-70
Schäfer, Michal; Humphries, Stephen; Stenmark, Kurt R et al. (2018) 4D-flow cardiac magnetic resonance-derived vorticity is sensitive marker of left ventricular diastolic dysfunction in patients with mild-to-moderate chronic obstructive pulmonary disease. Eur Heart J Cardiovasc Imaging 19:415-424
D'Alessandro, Angelo; El Kasmi, Karim C; Plecitá-Hlavatá, Lydie et al. (2018) Hallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming. Antioxid Redox Signal 28:230-250
Karoor, Vijaya; Fini, Mehdi A; Loomis, Zoe et al. (2018) Sustained Activation of Rho GTPases Promotes a Synthetic Pulmonary Artery Smooth Muscle Cell Phenotype in Neprilysin Null Mice. Arterioscler Thromb Vasc Biol 38:154-163
Stenmark, Kurt R; Graham, Brian B (2018) Urocortin 2: will a drug targeting both the vasculature and the right ventricle be the future of pulmonary hypertension therapy? Cardiovasc Res 114:1057-1059
Madhavan, Krishna; Frid, Maria G; Hunter, Kendall et al. (2018) Development of an electrospun biomimetic polyurea scaffold suitable for vascular grafting. J Biomed Mater Res B Appl Biomater 106:278-290

Showing the most recent 10 out of 148 publications